Χώρα: Ηνωμένες Πολιτείες
Γλώσσα: Αγγλικά
Πηγή: NLM (National Library of Medicine)
TRAZODONE HYDROCHLORIDE (UNII: 6E8ZO8LRNM) (TRAZODONE - UNII:YBK48BXK30)
NuCare Pharmaceuticals, Inc.
TRAZODONE HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE 100 mg
ORAL
PRESCRIPTION DRUG
Trazodone hydrochloride tablets, USP are indicated for the treatment of major depressive disorder (MDD) in adults. The efficacy of trazodone hydrochloride tablets, USP has been established in trials with the immediate release formulation of trazodone [see Clinical Studies (14)]. None. Teratogenic Effects Pregnancy Category C Trazodone hydrochloride has been shown to cause increased fetal resorption and other adverse effects on the fetus in two studies using the rat when given at dose levels approximately 30 to 50 times the proposed maximum human dose. There was also an increase in congenital anomalies in one of three rabbit studies at approximately 15 to 50 times the maximum human dose. There are no adequate and well-controlled studies in pregnant women. Trazodone hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Trazodone and/or its metabolites have been found in the milk of lactating rats, suggesting that the drug may be secreted in human
Trazodone Hydrochloride Tablets, USP 100 mg are available for oral administration as white, round, biconvex, tablets. Engraved “APO” bisect “T100” on one side, other side plain. Bottles of 30 NDC 68071-3256-3 Bottles of 45 NDC 68071-3256-5 Bottles of 60 NDC 68071-3256-6 Bottles of 90 NDC 68071-3256-9 -For 100 mg, break the score on either the left or right side of the tablet (two-thirds of a tablet). -For 100 mg, break the score on either the left or right side of the tablet (one-third of a tablet). Store at 20° to 25°C (68° to 77°F); excursions permitted from 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Dispense with a child-resistant closure in a tight, light-resistant container.
Abbreviated New Drug Application
NuCare Pharmaceuticals, Inc. ---------- MEDICATION GUIDE Trazodone hydrochloride tablets, USP (traz' oh done hye'' droe klor' ide) Read the Medication Guide that comes with trazodone hydrochloride tablets before you start taking it and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment. Talk to your healthcare provider or pharmacist if there is something you do not understand or you want to learn about trazodone hydrochloride tablets. What is the most important information I should know about trazodone hydrochloride tablets? Antidepressant medicines, depression or other serious mental illnesses, and suicidal thoughts or actions: Talk to your healthcare provider about: • All risks and benefits of treatment with antidepressant medicines • All treatment choices for depression or other serious mental illnesses 1. Antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, and young adults within the first few months of treatment. 2. Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a higher risk of having suicidal thoughts or actions. These include people who have or have a family history of bipolar illness (also called manic- depressive illness) or suicidal thoughts or actions. 3. How can I watch for and try to prevent suicidal thoughts and actions? • Pay close attention to any changes, especially sudden changes in mood, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is started or when the dose is changed. • Call your healthcare provider right away to report new or sudden changes in mood, behavior, thoughts or feelings. • Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you are worried about symptoms. Call a healthcare provider right Διαβάστε το πλήρες έγγραφο
TRAZODONE HYDROCHLORIDE- TRAZODONE HYDROCHLORIDE TABLET NUCARE PHARMACEUTICALS, INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE TRAZODONE HYDROCHLORIDE TABLETS, USP SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR TRAZODONE HYDROCHLORIDE TABLETS, USP. TRAZODONE HYDROCHLORIDE TABLETS, USP FOR ORAL USE INITIAL U.S. APPROVAL: 1981 WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ INCREASED RISK OF SUICIDAL THINKING AND BEHAVIOR IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS TAKING ANTIDEPRESSANTS FOR MAJOR DEPRESSIVE DISORDER (MDD) AND OTHER PSYCHIATRIC DISORDERS. TRAZODONE IS NOT APPROVED FOR USE IN PEDIATRIC PATIENTS ( 5.1). RECENT MAJOR CHANGES Warnings and Precautions ( 5.12) 08/2014 INDICATIONS AND USAGE Trazodone hydrochloride tablets, USP are indicated for the treatment of major depressive disorder ( 1). Efficacy was established in trials of trazodone immediate release formulation in patients with major depressive disorder ( 14). DOSAGE AND ADMINISTRATION Starting dose: 150 mg in divided doses daily. May be increased by 50 mg per day every three to four days. Maximum dose: 400 mg per day in divided doses ( 2). Trazodone hydrochloride tablets should be taken shortly after a meal or light snack ( 2). Tablets should be swallowed whole or broken in half along the score line, and should not be chewed or crushed ( 2). When discontinued, gradual dose reduction is recommended ( 2). DOSAGE FORMS AND STRENGTHS Bisectable tablets of 50mg, 100mg ,150 mg and 300 mg ( 3). CONTRAINDICATIONS None ( 4). WARNINGS AND PRECAUTIONS Clinical Worsening/Suicide Risk: Monitor for clinical worsening and suicidal thinking and behavior ( 5.1). Serotonin Syndrome or Neuroleptic Malignant Syndrome-Like Reactions: Have been reported with antidepressants. Discontinue trazodone hydrochloride tablets and initiate supportive treatment ( 5.2, 7). Activation of Mania/Hypomania: Screen for bipolar disorder and Διαβάστε το πλήρες έγγραφο